Medicinova AI Stock Analysis
Medicinova (MNOV) AI Stock Analysis
Medicinova
(NASDAQ:MNOV)
No summary available
Medicinova (MNOV) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $68.66M
- Dividend Yield
- ―
- Average Volume (3M)
- 331.78K
- Price to Earnings (P/E)
- -6.4
- Beta (1Y)
- 0.57
- Revenue Growth
- 262.80%
- EPS Growth
- 12.54%
- Country
- US
- Employees
- 6
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Medicinova Business Overview & Revenue Model
Company Description
MediciNova, Inc. is a biopharmaceutical firm dedicated to discovering and advancing innovative small molecule therapies for severe illnesses where current treatments are insufficient within the United States. Its robust development pipeline features...
Medicinova Risk Analysis
Medicinova disclosed 49 risk factors in its most recent earnings report. Medicinova reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksMedicinova Peers Comparison
Overall Rating
DTIL58Neutral
ACRV52Neutral
CAMP46Neutral
ALGS38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 58Neutral | $211.33M | -6.15 | -58.09% | ― | 6353.01% | 84.80% | |
| 52Neutral | $62.14M | -0.77 | -70.14% | ― | ― | 16.04% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 46Neutral | $238.47M | -1.85 | -261.83% | ― | 39.93% | 16.95% | |
| 38Underperform | $14.80M | -0.33 | -206.30% | ― | 1171.58% | 49.20% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| MNOV | Medicinova | 1.40 | -0.01 | -1.06% | |
| DTIL | Precision Biosciences | 7.57 | 2.43 | 47.18% | |
| ALGS | Aligos Therapeutics, Inc. | 2.10 | -4.92 | -70.09% | |
| ACRV | Acrivon Therapeutics, Inc. | 1.45 | -0.93 | -39.08% | |
| CAMP | CAMP4 Therapeutics Corporation | 3.80 | -0.19 | -4.76% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
